Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to prevent port site herniation caused by improper closure. It is involved in the medical device contract manufacturing; and manufacture and sale of injection molding and components of medical devices. The company was incorporated in 2012 and is based in Taipei, Taiwan.
Metrics to compare | 6499 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6499PeersSector | |
|---|---|---|---|---|
P/E Ratio | −9.8x | −75.5x | −0.5x | |
PEG Ratio | −1.35 | −0.98 | 0.00 | |
Price/Book | 6.2x | 5.1x | 2.6x | |
Price / LTM Sales | 19.1x | 5.5x | 3.2x | |
Upside (Analyst Target) | 150.0% | 49.7% | 51.4% | |
Fair Value Upside | Unlock | −1.3% | 8.5% | Unlock |